Physician profile
Sumaira Shafi
NPI 1164859278
$1,153.76
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $16.14 · 2021: $263 · 2022: $201.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $119.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $117.41 | 2019-2022 | |
| Incyte Corporation | $97.47 | 2019-2022 | |
| Seagen INC. | $95.00 | 2021 | |
| Abbvie INC. | $91.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $89.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $65.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $64.04 | 2019 | |
| Kyowa Kirin, INC. | $39.87 | 2019 | |
| Amag Pharmaceuticals, INC. | $38.59 | 2019 | |
| Aptevo Therapeutics INC | $34.50 | 2019 | |
| Eisai INC. | $32.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.83 | 2019 | |
| Emd Serono, INC. | $29.61 | 2019 | |
| Genentech USA, INC. | $28.88 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.76 | 2019 | |
| Daiichi Sankyo INC. | $21.26 | 2022 | |
| Celgene Corporation | $19.69 | 2022 | |
| Rigel Pharmaceuticals, INC. | $18.62 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.56 | 2019 | |
| Amgen INC. | $16.45 | 2019 | |
| Pfizer INC. | $16.11 | 2019 | |
| Stemline Therapeutics INC. | $16.05 | 2019 | |
| Puma Biotechnology, INC. | $13.73 | 2019 | |
| Genzyme Corporation | $12.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumaira Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.